Andere Kunden interessierten sich auch für
![Design, Synthesis & Biological Evaluation Of Novel Combi-heterocyclics]( "Design, Synthesis & Biological Evaluation Of Novel Combi-heterocyclics")
Design, Synthesis & Biological Evaluation Of Novel Combi-heterocyclics74,99 €![Design, Synthesis and Evaluation of Some Novel Heterocyclic Compounds]( "Design, Synthesis and Evaluation of Some Novel Heterocyclic Compounds")
Design, Synthesis and Evaluation of Some Novel Heterocyclic Compounds26,99 €![Design, synthesis and anti-HIV activity of curcumin analogues]( "Design, synthesis and anti-HIV activity of curcumin analogues")
Design, synthesis and anti-HIV activity of curcumin analogues26,99 €![Epilepsy: Novel GABA modulating agents and GABAergic imbalance in CNS]( "Epilepsy: Novel GABA modulating agents and GABAergic imbalance in CNS")
Epilepsy: Novel GABA modulating agents and GABAergic imbalance in CNS51,99 €![Design, Synthesis and Evaluation of Small Molecules as ALK5 Inhibitors]( "Design, Synthesis and Evaluation of Small Molecules as ALK5 Inhibitors")
Design, Synthesis and Evaluation of Small Molecules as ALK5 Inhibitors26,99 €![Design, Development and QSAR studies of 1, 2, 4-triazole compounds]( "Design, Development and QSAR studies of 1, 2, 4-triazole compounds")
Design, Development and QSAR studies of 1, 2, 4-triazole compounds39,99 €![Design, Synthesis and Biological Evaluation of substituted Triazine]( "Design, Synthesis and Biological Evaluation of substituted Triazine")
Design, Synthesis and Biological Evaluation of substituted Triazine23,99 €
Tuberculosis (TB) is an airborne global disease, which is typically caused by the Gram-positive bacterium Mycobacterium tuberculosis (Mtb). It remains to be one of the major infectious diseases globally.Despite 40 years of anti-TB chemotherapy, tuberculosis remains one of the leading infectious diseases worldwide. Among the main obstacles to the global control of the disease are the HIV epidemic that has dramatically increased risk for developing active TB, the increasing emergence of multi-drug resistant TB and the recalcitrance of persistent infections to treatment with conventional anti-TB drugs.The situation is exacerbated by the increasing emergence of extensively drug-resistant TB. A potential approach to overcome the resistance problem is to design novel and innovative agents. The development of new antibiotics can be achieved from derivatives of known antimicrobial agents or by identification of novel agents active against previously unexploited targets.Thus, keeping in view the need of novel antibacterial agents with improved antimicrobial profile, and as a part of our ongoing programme on design and discovery of novel pharmacotherapeutic and antimicrobial agents.